Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046193 | 0.78 | ALDH1A1 (0.39) | KMT2AALDH1A1TSHRMEN1KDM4E | |
| SCHEMBL623602 | 0.74 | TSHR (0.45) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL15276734 | 0.74 | AKR1C3 (0.43) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL1974281 | 0.72 | GSK3B (0.44) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| Hydrochloric Acid SCHEMBL29045760 | 0.72 | TSHR (0.43) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL28386054 | 0.71 | DAO (0.39) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL365155 | 0.71 | DAO (0.42) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL27712627 | 0.71 | KMT2A (0.52) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL157848 | 0.71 | DAO (0.63) | DAOKMT2AALDH1A1TSHRAKR1C4 | |
| SCHEMBL4442166 | 0.70 | ERN1 (0.39) | KMT2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-3237420-B1 | ERK INHIBITORS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3237420-A1 | ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-9312491-B2 | Polymer and photoelectric conversion element | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20140000716-A1 | POLYMER AND PHOTOELECTRIC CONVERSION ELEMENT | NATIONAL UNIVERSITY CORPORATION OF HIROSHIMA UNIVERSITY (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267691-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | DAO 3411/4885KMT2A 3179/4885ALDH1A1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.